跳至主要内容
临床试验/NCT02063113
NCT02063113终止不适用

Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.

Nantes University Hospital3 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2014年5月19日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
48
试验地点
3
主要终点
The occurrence of the events

研究概览

简要总结

The aim of this study is to determine whether the presence of vulnerability detected by geriatricians is associated with treatment discontinuation in older patient. During the comprehensive geriatric assessment realized before the decision-treatment, the following data are recorded and their impact in the therapeutic changes will also be analysed: comorbidity, age, depression, functional status, the cognitive impairment and malnutrition.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
70 Years 至 100 Years(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged 70 years and older
  • Patients referred for a assessment of a newly diagnosed multiple myeloma
  • Patients for who the initial therapy proposed is either melphalan-prednisone-thalidomide or melphalan-prednisone-bortezomib or included in a phase 3 trial.
  • Patients who provide informed written consent

排除标准

  • Patients who refuse the study
  • Patients who won't have therapy
  • Patients can't respond to geriatric assessment because of severe cognitive disorder
  • Patients with a legal guardian

结局指标

主要结局

The occurrence of the events

时间窗: 6 MONTHS

The primary outcome is either : * early interruption of treatment * dose reduction \> 20% during treatment * discontinuous treatment These outcomes will be measured every 6 months during the 2 years of follow up

次要结局

  • Progression to 1 and 2 years(1 year/2year)
  • Type of Vulnerability(6 MONTHS)
  • Therapeutic changes(6 MONTHS)
  • Toxicity during treatment(6 months)
  • Complete response at 1 and 2 years(1 year/2 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验